Study guide
10.2 Central Nervous System Depressants and Stimulants
National Certified Peer Recovery Support Specialist NCPRSS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction to the NCPRSS Examination
1.1 NCPRSS Exam Structure, Credentialing, and Eligibility 1.2 Study Framework, Exam Strategies, and Navigating Test Scenarios
2 Chapter 2: Foundations of the Peer Recovery Support Role
2.1 Defining the Peer Role: Lived Experience and Mutuality 2.2 Scope of Practice and Non-Clinical Role Boundaries 2.3 Differentiating the Peer Specialist from Clinical and Support Roles
3 Chapter 3: Peer Engagement, Advocacy, Intake, and Service Coordination
3.1 Relationship Building and Active Listening in Peer Work 3.2 Individual and Systems-Level Peer Advocacy 3.3 Community Resource Navigation and Connection 3.4 Screening and Intake: The Peer's Role at First Contact 3.5 Recognizing Indicators of Substance Use and Co-Occurring Disorders for Referral 3.6 Case Management and Service Coordination in Peer Practice
4 Chapter 4: Cultural Humility, Trauma-Informed Peer Support, and Self-Care
4.1 Cultural Humility and Diversity in Peer Support 4.2 Trauma-Informed Peer Principles and Safety 4.3 Peer Specialist Self-Care and Burnout Prevention 4.4 Reflective Supervision and Professional Growth
5 Chapter 5: Recovery Paradigms, Definitions, and Recovery Capital
5.1 Definitions, Principles, and Dimensions of Recovery 5.2 Recovery-Oriented Systems of Care (ROSC) 5.3 Recovery Capital Assessment and Growth
6 Chapter 6: Stages of Change and Motivational Interviewing in Peer Support
6.1 The Transtheoretical Model: Stages of Change 6.2 Motivational Interviewing Spirit and Principles 6.3 Core MI Communication Skills: OARS and Change Talk
7 Chapter 7: Diverse Pathways to Recovery
7.1 Mutual Aid and 12-Step Pathways 7.2 Secular, Cognitive, and Faith-Based Pathways 7.3 Harm Reduction and Medication-Assisted Pathways
8 Chapter 8: Person-Centered Recovery Planning and Crisis Support
8.1 Person-Centered Goal Setting and Strengths Assessment 8.2 Wellness Recovery Action Planning (WRAP) and Recovery Plans 8.3 De-escalation and Crisis Intervention in Peer Practice 8.4 Suicide Risk Recognition, Safety Planning, and 988 Lifeline
9 Chapter 9: Recovery Documentation, Communication, and Recurrence Support
9.1 Peer Documentation and Record Keeping Standards 9.2 Lapse, Relapse, and Recurrence Management 9.3 Family Systems and Peer Support for Loved Ones
10 Chapter 10: Addiction Neurobiology and Substance Classes
10.1 Neurobiology of Addiction and the Brain Reward System 10.2 Central Nervous System Depressants and Stimulants 10.3 Opioids, Cannabis, Hallucinogens, and Emerging Synthetics
11 Chapter 11: Medications, Overdose Response, and Infectious Disease Prevention
11.1 Medications for Opioid Use Disorder (MOUD) 11.2 Medications for Alcohol and Tobacco Use Disorders 11.3 Overdose Recognition, Naloxone Administration, and Post-Reversal Care 11.4 HIV, Viral Hepatitis, and Other Pathogens: Prevention, Testing, and Linkage
12 Chapter 12: Ethical Standards and Professional Boundaries
12.1 NAADAC/NCC AP Code of Ethics and Peer Standards 12.2 Dual Relationships, Power Dynamics, and Boundaries 12.3 Managing Conflicts of Interest and Personal Conduct
13 Chapter 13: Legal Regulations, Confidentiality, and Mandated Reporting
13.1 Federal Confidentiality Laws: 42 CFR Part 2 and HIPAA 13.2 Exceptions to Confidentiality and Permitted Disclosures 13.3 Mandated Reporting and Duty to Warn/Protect
14 Chapter 14: Peer Rights, Informed Consent, and Credential Maintenance
14.1 Peer Rights, Autonomy, and Informed Consent 14.2 NCPRSS Credential Maintenance, Renewal, and Professional Development
10.2 Central Nervous System Depressants and Stimulants
Key Takeaways Explain This Topic AI
Central Nervous System (CNS) depressants (alcohol, benzodiazepines, barbiturates) potentiate GABA-A receptors and inhibit glutamate, slowing vital physiological functions including respiration, heart rate, and neural transmission.
Depressant withdrawal is unique and uniquely dangerous: unlike opioid or stimulant withdrawal, abrupt cessation of heavy, chronic alcohol or benzodiazepine use can produce fatal autonomic storms, grand mal seizures, and Delirium Tremens (DTs).
Depressant withdrawal can NEVER be 'toughed out' at home or managed with non-medical peer remedies; peer specialists must treat depressant detox as an urgent medical priority requiring medically managed inpatient detoxification.
Central Nervous System stimulants (cocaine, methamphetamine, amphetamine salts, methylphenidate) surge synaptic dopamine and norepinephrine, producing intense euphoria, hypervigilance, anorexia, and cardiovascular strain.
Stimulant toxicity can cause life-threatening emergencies, including severe hyperthermia, heart attack, stroke, and hyperactive delirium with severe agitation, that require an immediate 911 call.
Last updated: October 2026
10.2 Central Nervous System Depressants and Stimulants
Note
Quick Answer: Central Nervous System (CNS) depressants and stimulants represent two opposing pharmacological classes with profound clinical and safety implications. CNS Depressants (alcohol, benzodiazepines, barbiturates) enhance inhibitory GABA activity and suppress excitatory Glutamate , slowing neurological functioning. CRITICAL EXAM PRINCIPLE: Abrupt cessation from chronic depressants can be fatal due to rebound autonomic hyperactivity, grand mal seizures, and Delirium Tremens (DTs) ; depressant withdrawal can never be 'toughed out' and mandates immediate medical detoxification. Conversely, CNS Stimulants (cocaine, methamphetamine, prescription amphetamines) trigger massive synaptic surges of dopamine and norepinephrine , producing hyper-arousal, hyperthermia, and cardiovascular strain. While stimulant withdrawal (the "crash") is rarely fatal, it brings severe depression, high suicide risk, and exhaustion, while acute stimulant toxicity can cause lethal cardiac arrest, stroke, and hyperactive delirium with severe agitation requiring emergency medical services (911).
Central Nervous System (CNS) Depressants: Pharmacology and Mechanisms
Central Nervous System depressants are substances that decrease neuronal activity throughout the brain and spinal cord. They achieve this primarily through interaction with the brain's major inhibitory neurotransmitter, Gamma-Aminobutyric Acid (GABA) , and specifically the GABA-A receptor complex .
The GABA-A receptor is an ionotropic receptor linked to a central chloride ion channel. When GABA binds to this receptor, the channel opens, allowing negatively charged chloride ions ( C l − Cl^- C l − ) to flow into the neuron. This hyperpolarizes the cell membrane, making it significantly harder for the neuron to generate an electrical action potential. In plain language, GABA acts as the brain's physiological "braking system." [ GABA-A RECEPTOR COMPLEX ]
- │
- ┌───────────────────────┴───────────────────────┐
- ▼ ▼
- [ ALCOHOL BINDING ] [ BENZODIAZEPINE BINDING ]
- Enhances GABA-A receptor function Increases channel opening frequency
- │ │
- └───────────────────────┬───────────────────────┘
- │
- ▼
- MASSIVE INFLUX OF CHLORIDE (Cl-)
- │
- ▼
- NEURONAL HYPERPOLARIZATION
- (Severe inhibition of brain activity)
- │
- ┌──────────────────────────────────┴──────────────────────────────────┐
- ▼ ▼ ▼
- SEDATION SLURRED SPEECH / ATAXIA RESPIRATORY DEPRESSION
- Profiles of Major Depressants
Alcohol (Ethanol) :
Mechanism : Modulates GABA-A receptors (increasing chloride influx), inhibits excitatory NMDA glutamate receptors, and stimulates endogenous opioid and dopamine release.
Intoxication Profile : Euphoria and disinhibition at lower doses; progressive slurred speech, ataxia (loss of motor coordination), nystagmus (involuntary eye twitching), stupor, and respiratory arrest at elevated Blood Alcohol Concentrations (BAC ≥ 0.30 \ge 0.30 ≥ 0.30 g/dL).
Benzodiazepines :
Examples : Alprazolam (Xanax), Clonazepam (Klonopin), Diazepam (Valium), Lorazepam (Ativan), Temazepam (Restoril).
Mechanism : Act as Positive Allosteric Modulators (PAMs) at GABA-A receptors. They do not open the chloride channel directly; instead, they increase the frequency with which the channel opens in the presence of GABA.
Clinical Indication & Risks : Prescribed medically for acute panic, generalized anxiety, insomnia, muscle spasms, and acute seizure management. Highly prone to tolerance and severe physiological dependence, especially when combined with alcohol or opioids (exponentially multiplying fatal respiratory depression).
Barbiturates :
Examples : Phenobarbital, Secobarbital, Butalbital.
Mechanism : Bind directly to GABA-A receptors and increase the duration of chloride channel opening. At higher doses, barbiturates can open the chloride channel even in the absence of GABA .
Clinical Significance : Extremely narrow therapeutic index (tiny margin between therapeutic dose and lethal toxicity). Largely replaced by benzodiazepines in clinical medicine, but still encountered in seizure management, migraine cocktails, and illicit markets. Overdose carries extreme mortality due to direct central respiratory and cardiovascular collapse.
CRITICAL EXAM FOCUS: The Life-Threatening Nature of Depressant Withdrawal
Caution
THE CARDINAL SAFETY RULE OF PEER PRACTICE: While opioid withdrawal is intensely painful and agonizing, it is rarely fatal in isolation for healthy individuals. In sharp contrast, Central Nervous System Depressant withdrawal (alcohol, benzodiazepines, barbiturates) can be directly and unpredictably FATAL. Under no circumstances should a peer recovery support specialist ever encourage, support, or allow a participant with chronic, heavy alcohol or benzodiazepine dependence to "sweat it out," "tough it out," or detox at home without professional medical supervision.
The Pathophysiology of Depressant Withdrawal
To understand why depressant withdrawal kills, one must examine chronic neuroadaptation:
Chronic Brake Application : Heavy daily alcohol or benzodiazepine consumption forces the brain to endure continuous, excessive GABA inhibition.
Compensatory Counter-Adaptation : To survive and keep breathing, the brain defends homeostasis by down-regulating GABA receptors (loosening the brakes) and up-regulating excitatory NMDA glutamate receptors (stepping on the gas pedal).
Abrupt Removal of the Drug : When the individual abruptly stops drinking or taking benzodiazepines, the exogenous GABA facilitation instantly vanishes. However, the compensatory changes remain! The brain is left with blunted, down-regulated GABA brakes and an over-abundant, hyper-sensitized glutamate gas pedal.
Glutamate Excitotoxic Storm : Unopposed glutamate floods the central nervous system, producing uncontrollable neuronal firing, massive sympathetic nervous system hyperarousal, cardiac dysrhythmias, malignant hypertension, hyperthermia, grand mal seizures, and death. ┌────────────────────────────────────────────────────────────────────────┐
- │ TIMELINE OF UNTREATED ALCOHOL WITHDRAWAL SYNDROME │
- ├──────────────────────────┬─────────────────────────────────────────────┤
- │ TIMEFRAME AFTER LAST USE │ CLINICAL SIGNS AND PHYSIOLOGICAL RISKS │
- ├──────────────────────────┼─────────────────────────────────────────────┤
- │ 6 to 12 Hours │ • Minor Withdrawal: Tremulousness ("shakes"),│
- │ │ sweating, anxiety, insomnia, nausea, │
- │ │ tachycardia, elevated blood pressure │
- ├──────────────────────────┼─────────────────────────────────────────────┤
- │ 12 to 24 Hours │ • Alcoholic Hallucinosis: Visual, tactile, │
- │ │ or auditory hallucinations; clear sensorium│
- │ │ (individual is oriented to reality) │
- ├──────────────────────────┼─────────────────────────────────────────────┤
- │ 24 to 48 Hours │ • Withdrawal Seizures: Generalized tonic- │
- │ │ clonic (grand mal) seizures; high risk of │
- │ │ status epilepticus and head trauma │
- ├──────────────────────────┼─────────────────────────────────────────────┤
- │ 48 to 96 Hours │ • DELIRIUM TREMENS (DTs): Medical Emergency!│
- │ │ Profound confusion, disorientation, severe│
- │ │ autonomic storm (fever, extreme sweating, │
- │ │ tachycardia >120 bpm, severe tremors), │
- │ │ terrifying hallucinations. Can be fatal │
- │ │ without prompt medical treatment. │
- └──────────────────────────┴─────────────────────────────────────────────┘
- Benzodiazepine Withdrawal Nuances
Benzodiazepine withdrawal follows a similar excitatory trajectory but is heavily dictated by the elimination half-life of the specific drug:
Short-Acting Benzodiazepines (e.g., Alprazolam [Xanax], Lorazepam [Ativan]): Withdrawal onset is rapid (within 12 to 24 hours), intense, and rapidly progresses to panic, rebound insomnia, muscular fasciculations, and seizures.
Long-Acting Benzodiazepines (e.g., Diazepam [Valium], Clonazepam [Klonopin]): Withdrawal may not manifest for 3 to 7 days, or even up to 2 weeks post-cessation, often lulling the peer into a false sense of security before severe panic, delirium, or seizures abruptly strike.
Protracted Withdrawal : Benzodiazepine neuroadaptation can cause prolonged neurological instability lasting months, requiring specialized, gradual medical tapering protocols.
The Peer Specialist Action Protocol for Depressants
When a participant indicates they are planning to stop using alcohol or benzodiazepines cold turkey, the peer specialist must:
Immediately Educate and Validate : Gently but firmly inform the peer that alcohol and benzodiazepine withdrawal carries genuine risks of fatal seizures and cannot be safely navigated through willpower or home remedies.
Decline Unmonitored Detox Support : Never agree to "babysit" a peer through cold-turkey depressant detox in an apartment or private setting.
Facilitate Immediate Medical Detox : Connect the peer directly to a medically managed inpatient detoxification facility, hospital emergency department, or urgent behavioral health stabilization unit.
Utilize Validated Assessment Context : Be aware that medical facilities use tools like the CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, Revised) to guide symptom-triggered benzodiazepine dosing during alcohol withdrawal.
Central Nervous System (CNS) Stimulants: Pharmacology and Profiles
Central Nervous System stimulants are substances that accelerate neurological activity, stimulate the peripheral sympathetic nervous system, and produce heightened alertness, vigor, and euphoria. While depressants slow the brain, stimulants send it into biological overdrive.
Mechanism of Action: The Catecholamine Surge
Stimulants act primarily upon the catecholamine neurotransmitters —specifically Dopamine (DA) and Norepinephrine (NE) , and to a lesser extent Serotonin (5-HT) .
Dopamine Surge : Floods the nucleus accumbens and prefrontal cortex, generating intense euphoria, confidence, feelings of grandiosity, and intense focus.
Norepinephrine Surge : Triggers a massive "fight-or-flight" sympathetic nervous system discharge, increasing heart rate, constricting blood vessels, elevating blood pressure, dilating bronchioles, and suppressing appetite. ┌────────────────────────────────────────────────────────────────────────┐
- │ COMPARISON OF MAJOR CNS STIMULANT PHARMACODYNAMICS │
- ├──────────────────────────┬─────────────────────────────────────────────┤
- │ SUBSTANCE │ PHARMACOLOGICAL MECHANISM & KINETICS │
- ├──────────────────────────┼─────────────────────────────────────────────┤
- │ Cocaine Hydrochloride / │ • Pure Reuptake Inhibitor: Blocks DAT │
- │ Crack Cocaine │ (dopamine transporter), NET, and SERT │
- │ │ • Fast onset, very short half-life (~1 hour)│
- │ │ • Rapid, intense binge-crash pattern │
- ├──────────────────────────┼─────────────────────────────────────────────┤
- │ Methamphetamine / │ • Reuptake Blocker AND Releaser: Enters │
- │ Crystal Meth │ presynaptic terminals via DAT; reverses │
- │ │ VMAT2 (vesicular monoamine transporter 2);│
- │ │ dumps massive dopamine stores into synapse│
- │ │ and blocks MAO degradation enzymes │
- │ │ • Long half-life (10 to 12 hours) │
- │ │ • Severe neurotoxicity to dopamine axons │
- ├──────────────────────────┼─────────────────────────────────────────────┤
- │ Prescription Stimulants │ • Mixed amphetamine salts (Adderall) or │
- │ (Amphetamine Salts / │ Methylphenidate (Ritalin/Concerta) │
- │ Methylphenidate) │ • Block reuptake and stimulate release │
- │ │ • Formulated for controlled release; high │
- │ │ misuse liability when crushed or snorted │
- └──────────────────────────┴─────────────────────────────────────────────┘
- Intoxication vs. Crash / Withdrawal: The Stimulant Rollercoaster
Understanding the stark dichotomy between stimulant intoxication and stimulant withdrawal is critical for exam success and crisis de-escalation.
Stimulant Intoxication Profile
When actively intoxicated with high-potency stimulants, individuals present with:
Behavioral Signs : Rapid, pressured speech; grandiosity; flight of ideas; hypervigilance; motor agitation; pacing; teeth grinding ( bruxism ); decreased need for sleep; total anorexia.
Physical Signs : Dilated pupils ( mydriasis ); profuse sweating; tachycardia; hypertension; hyperactive reflexes; tremors.
Psychiatric Complications : Stimulant-induced paranoia, extreme suspicion, persecutory delusions, and auditory/visual hallucinations. Users frequently develop formication —the terrifying tactile hallucination that insects, parasites, or maggots are crawling under their skin (commonly called "crank bugs" or "coke bugs"), leading to compulsive skin-picking and open, excoriated sores.
Acute Stimulant Toxicity: Medical Emergencies
Unlike depressants where death occurs from slow, shallow breathing, stimulant toxicity kills through cardiovascular and thermal catastrophe:
Severe Hyperthermia : Core body temperature spikes dangerously ( > 104 ∘ F >104^{\circ}\text{F} > 10 4 ∘ F / 40 ∘ C 40^{\circ}\text{C} 4 0 ∘ C ), leading to rhabdomyolysis (muscle tissue breakdown), acute renal failure, and disseminated intravascular coagulation (DIC).
Cardiovascular Collapse : Severe coronary vasoconstriction combined with extreme tachycardia triggers acute myocardial infarction (heart attack), fatal ventricular arrhythmias, and aortic dissection.
Cerebrovascular Accident (Stroke) : Malignant hypertension ruptures cerebral blood vessels (hemorrhagic stroke) or creates vasospastic ischemic strokes.
Hyperactive Delirium with Severe Agitation : Extreme agitation, confusion, hyperthermia, and combativeness that can end in sudden cardiac arrest. (Major medical organizations, including the American College of Emergency Physicians, stopped using the older label "excited delirium" in 2023.) Requires immediate 911 dispatch.
The Stimulant "Crash" and Post-Acute Withdrawal
Because presynaptic dopamine stores are completely exhausted following a stimulant binge, the cessation of stimulant use results in a profound neurochemical deficit state known as the crash :
Physical Exhaustion and Hypersomnia : The individual may sleep for 18 to 36 hours continuously, waking only briefly with an intense, ravenous appetite ( hyperphagia ).
Profound Dysphoria and Anhedonia : The individual experiences crushing emotional depression, feeling completely devoid of joy, motivation, or energy.
High Suicide Risk : The precipitous plunge in dopamine and serotonin levels can trigger acute, intense suicidal ideation. Assessing safety and suicide risk during a stimulant crash is a mandatory peer responsibility.
Intense Psychological Craving : Even amidst physical exhaustion, the individual experiences overwhelming cravings to re-administer the stimulant to escape the psychic agony of the crash.
Warning
While stimulant withdrawal does not carry the direct seizure-and-death profile of alcohol or benzodiazepine withdrawal, its mortality risk lies in acute psychiatric crisis and suicide . Any peer experiencing a severe post-stimulant crash must be screened for suicidal thoughts and offered immediate, supportive monitoring.
Peer Recovery Strategies for Depressants and Stimulants
Substance Class Acute Crisis Presentation Peer Specialist Immediate Priority Non-Clinical Recovery Strategies
CNS Depressants (Alcohol, Benzodiazepines) Tremors, sweating, confusion, history of seizures, sudden cold turkey cessation URGENT MEDICAL SAFETY: Immediate referral and transport to medically managed inpatient detox; never attempt unassisted peer detox Support recovery planning post-detox; address underlying anxiety; explore MAT options (acamprosate, naltrexone); facilitate mutual aid connections
CNS Stimulants (Cocaine, Methamphetamine) Paranoia, agitation, chest pain, hyperthermia, formication ("bugs"), crash depression DE-ESCALATION & TOXICITY CHECK: Call 911 for chest pain/hyperthermia; move to low-stimulation, quiet environment; check for suicide risk during crash Grounding techniques; hydration and nutrition; sleep hygiene; harm reduction (sterile pipes, contingency management incentives); validate that anhedonia will heal